Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance

小细胞肺癌细胞中Bax表达降低不足以诱导顺铂耐药性

阅读:1

Abstract

Resistance to cisplatin in the course of chemotherapy contributes to the poor prognosis of small cell lung cancer (SCLC). B cell lymphoma-2 is the founding member of a large family of proteins that either promote or inhibit apoptosis. We aimed at investigating if the pro-apoptotic members Bad, Bax, Bim and Bid are involved in cisplatin-resistance. - Cisplatin-resistance in the SCLC cell line H1339 was induced by repetitive exposure to cisplatin. Protein expression was quantified by Western Blot and immuno-fluorescence analysis. Protein expression was altered using siRNA interference. - Four cycles of 0.5 μg/ml cisplatin led to partial cisplatin-resistance in H1339 cells. The expression of Bad, Bim and Bid was comparable in naive and resistant cells while the expression of Bax was reduced in the resistant clone. But, reducing Bax expression in naive cells did not lead to altered cisplatin sensitivity neither in H1339 nor in H187 SCLC cells. - We conclude that the reduced Bax expression after exposure to cisplatin is not sufficient to induce cisplatin-resistance in SCLC cells.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。